After yet another PhIII Alzheimer's failure, experts try to map a path out of the wrecking field
Pushed by a 15-year record of clinical failures and pulled by an FDA searching for a practical new path forward for Alzheimer’s drug research, a joint committee organized by the NIH’s National Institute of Aging and the Alzheimer’s Association is suggesting a biomarker-based approach to defining the illness that can guide new development efforts.
In place of the old toxic protein debate that once divided the field into two camps for amyloid beta and tau, the group believes that the presence of both should be a hallmark of Alzheimer’s, along with physical evidence of neurodegeneration or neuronal injury. By mixing and matching the biomarkers, they want to be able to highlight the development of the disease into a set of distinct stages that can be used to test the effectiveness of new drugs and combination therapies even before symptoms appear.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters